# Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications

**In short:** DEA and HHS extended, through December 31, 2026, the telemedicine flexibilities in place since the COVID-19 public health emergency for prescribing controlled medications. Until then, a DEA-registered practitioner may prescribe schedule II-V controlled substances via telemedicine to a patient without an in-person medical evaluation, if the prescription is for a legitimate medical purpose, uses an interactive telecommunications system and meets the other conditions of 21 CFR 1307.41(c). The rule took effect on January 1, 2026.

21 CFR 1307.41; 42 CFR 12.1 (Fourth Temporary Extension, 90 FR 61301; Docket No. DEA-407) · Healthcare · Operations & Workforce. Published November 14, 2026. Last reviewed November 14, 2026.

## At a glance

- Citation: 21 CFR 1307.41; 42 CFR 12.1 (Fourth Temporary Extension, 90 FR 61301; Docket No. DEA-407)
- Issued by: Drug Enforcement Administration, Department of Health and Human Services
- Type: Final rule
- Status: Effective (as of November 14, 2026) [2] This is a temporary rule. The current text of 21 CFR 1307.41 states that the section is in effect until the end of the day December 31, 2026. [2]
- Applies to: DEA-registered practitioners, and practitioners exempt from registration under 21 U.S.C. 822(d), who prescribe schedule II-V controlled substances via telemedicine to patients they have not evaluated in person.
- Jurisdiction: United States (federal)

## Key dates

Each date ends with the number of its source in "Sources". Dates were checked on November 14, 2026 unless the row gives another date.

| Date | Kind | What | Source |
|---|---|---|---|
| December 31, 2025 | Published | Fourth temporary rule published in the Federal Register (90 FR 61301) | [1] |
| January 1, 2026 | Effective | Fourth temporary extension takes effect | [1] |
| December 31, 2026 | Deadline | Telemedicine prescribing flexibilities expire at the end of this day | [2] |

## What it changed

The fourth temporary rule amends 21 CFR 1307.41 and 42 CFR 12.1 so that the authorization expires at the end of December 31, 2026 instead of December 31, 2025. It sits alongside two final rules published on January 17, 2025, for buprenorphine treatment and for Veterans Affairs patients, which the rule says go into effect on December 31, 2025.

## Not listed

- The temporary rule describes DEA's separate proposal for a Special Registration for Telemedicine (90 FR 6541, January 17, 2025). That is a different rulemaking, so its dates are not listed here. [3]

## Sources

1. Office of the Federal Register (Federal Register API). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, FR Doc. 2025-24123 (90 FR 61301, December 31, 2025), Federal Register API record. <https://www.federalregister.gov/api/v1/documents/2025-24123.json> Checked November 14, 2026.
2. Electronic Code of Federal Regulations (Office of the Federal Register). 21 CFR 1307.41, Temporary extension of certain COVID-19 telemedicine flexibilities for prescription of controlled medications (eCFR current to November 12, 2026). <https://www.ecfr.gov/current/title-21/section-1307.41> Checked November 14, 2026.
3. Drug Enforcement Administration. Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications, public inspection copy of FR Doc. 2025-24123. <https://public-inspection.federalregister.gov/2025-24123.pdf> Checked November 14, 2026.

Last reviewed: November 14, 2026
Canonical URL: <https://insights.moraph.com/rules/21-cfr-1307-41-telemedicine-flexibilities>
Publisher: Moraph Insights
